Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedActivity from announced rounds
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Pitching Soleus Capital? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room